GLG News by Ranexa Prescribers for Angina: Cardiologists (US)

The good news gets better as there is now data from MERLIN that corroborates the news from CARISA showing a reduction in HbGA1C that was significant.

Ask any patient with diabetes what they want for a therapeutic option and they'll tell you non-injectable insulin.  They understand that all the other medications are a poor substitution for the replacement of pancreatic insulin and they are tired of taking multiple pills each day. So why did...

The failure of drug eluting stents in the eyes of the public and in the medical community is probably not a failure of the device as much as a failure of patient managment.  It is clear that atherothrombotic vascular disease requires a life-long commitment to blood pressure, cholesterol, and blood...

The approval of Galvus in Europe increases the pressure on the FDA to approve its use in the United Status.

Market impact is huge for many reasons. First, carvedilol is postulated to be a more effective beta blocker in the management of CHF with reduced ejection fraction compared to other generics and name brand ones on the market. This is based on a number of clinical trials demonstrating superiority in...

The repositioning of the hole, also present with the VIP version is a mild improvement to decrease sheath manipulation. Otherwise the device has not changed much in the past few years. While a very good device in general, its primary limitaions listed below still remain. 1. not allowing re-access...

Fexofenadine-Allegra is usually perceived as slightly less effective than Claritin for seasonal allergic rhinitis. Both of these drug are non-sedating. Zyrtec, however, with slight sedation potential is the most powerful of the group.

Newly introduced guidelines for treatment targets in hypertensive patients target lower blood pressures than  those previously suggested by JNC.  Since it has already been demonstrated that control of BP to current targets in many hypertensives requires three or more drugs, even lower targets...

It is clear that the panel felt that there was inadequate data on the psychiatric implications of rimonabant. It is a strong statement coming in the wake of the rosiglitazone mess (with strong recollections of cerivastatin and Vioxx) demonstrating that the FDA will be very finicky about approvals in...

It is clear that the advisory panel is more concerned with safety in a limited population that the broader impact of obesity and its metabolic problems and acceleration of diabetes and atherosclerosis. This demonstrates the likelihood that the FDA will likely be posturing to reflect the rosiglitazone...